keyword
MENU ▼
Read by QxMD icon Read
search

progression after second line chemotherapy prostate cancer

keyword
https://www.readbyqxmd.com/read/27903924/randomized-phase-ii-study-of-cabazitaxel-versus-methotrexate-in-patients-with-recurrent-and-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-previously-treated-with-platinum-based-therapy
#1
Jean-Pascal Henry Machiels, Aline Van Maanen, Jean-Marie Vandenbulcke, Bertrand Filleul, Emmanuel Seront, Stéphanie Henry, Lionel D'Hondt, Christophe Lonchay, Stéphane Holbrechts, Petra Boegner, Dany Brohee, Didier Dequanter, Ingrid Louviaux, Brieuc Sautois, Nicolas Whenham, Guy Berchem, Brigitte Vanderschueren, Christel Fontaine, Sandra Schmitz, Aline Gillain, Joelle Schoonjans, Sylvie Rottey
LESSONS LEARNED: Cabazitaxel has activity in squamous cell carcinoma of the head and neck (SCCHN) and taxane-resistant cell lines. For the first time, cabazitaxel was investigated in incurable patients with recurrent SCCHN. Patients were randomly assigned to cabazitaxel every 3 weeks or weekly methotrexate.This phase II study did not meet its primary endpoint.Cabazitaxel has low activity in SCCHN.The toxicity profile in this population also was not favorable owing to the high rate of febrile neutropenia observed (17%)...
November 30, 2016: Oncologist
https://www.readbyqxmd.com/read/27890446/efficacy-of-therapies-after-galeterone-in-patients-with-castration-resistant-prostate-cancer
#2
Rana R McKay, Lillian Werner, Matthew Fiorillo, Jennifer Roberts, Elisabeth I Heath, Glenn J Bubley, Robert Bruce Montgomery, Mary-Ellen Taplin
BACKGROUND: Galeterone is a multi-targeted agent with activity as a CYP17 inhibitor, androgen receptor antagonist, and also causes androgen receptor degradation. It has shown meaningful anti-tumor activity with a well-tolerated safety profile in patients with castration-resistant prostate cancer (CRPC) in phase I and II studies; however, the efficacy of currently approved CRPC therapies after treatment with galeterone is unknown. In this study, we evaluate prostate specific antigen (PSA) response of non-protocol therapies following galeterone in a subset of patients treated on the Androgen Receptor Modulation Optimized for Response (ARMOR) 2 study...
October 27, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27847099/efficacy-of-switching-therapy-of-luteinizing-hormone-releasing-hormone-analogue-for-advanced-prostate-cancer
#3
Yuan-Chi Shen, Chih-Hsiung Kang, Po-Hui Chiang
This study was conducted to determine the efficacy of switching therapy with a second-line luteinizing hormone-releasing hormone (LHRH) analogue after prostate-specific antigen (PSA) progression for advanced prostate cancer. We enrolled 200 patients, from December 2005 to September 2013, with nodal positive, metastatic prostate cancer or disease progression after definite treatment receiving continuous LHRH analogue therapy with monthly depot leuprorelin(sc) acetate 3.75 mg/vial (LA) or goserelin acetate(sc) 3...
November 2016: Kaohsiung Journal of Medical Sciences
https://www.readbyqxmd.com/read/27506431/-177-lu-dkfz-psma-617-therapy-in-metastatic-castration-resistant-prostate-cancer-safety-efficacy-and-quality-of-life-assessment
#4
Madhav Prasad Yadav, Sanjana Ballal, Madhavi Tripathi, Nishikant Avinash Damle, Ranjit Kumar Sahoo, Amlesh Seth, Chandrasekhar Bal
PURPOSE: The purpose of this study was to evaluate the efficacy and safety of a novel theranostic agent, (177)Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer (mCRPC). METHODS: Thirty-one mCRPC patients with progressive disease despite second-line hormonal therapy and/or docetaxel chemotherapy were recruited for the study. All patients underwent diagnostic(68)Ga-PSMA-HBED-CCPET/CT, prior to inclusion for therapy. Included patients then underwent quarterly (177)Lu-DKFZ-PSMA-617 therapy...
August 10, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27450512/enzalutamide-in-patients-with-castration-resistant-prostate-cancer-progressing-after-docetaxel-retrospective-analysis-of-the-swiss-enzalutamide-named-patient-program
#5
Dimitrios Papazoglou, Luciano Wannesson, Dominik Berthold, Richard Cathomas, Silke Gillessen, Christian Rothermundt, Loretta Hasler, Ralph Winterhalder, Andreas Barth, Walter Mingrone, Catrina Uhlmann Nussbaum, Lukas von Rohr, Philippe von Burg, Mathias Schmid, Jürg Richner, Sylvia Baumann, Reto Kühne, Frank Stenner, Sacha I Rothschild
BACKGROUND: Enzalutamide is a second-generation androgen receptor (AR) inhibitor that binds to and blocks the AR with higher affinity than previously available AR inhibitors. High activity has been proven in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and in chemotherapy-naive patients with mCRPC. However, its activity in patients previously treated with other novel agents (for example, abiraterone and/or cabazitaxel), remains controversial...
June 23, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27417317/phase-ii-study-of-a-novel-taxane-cabazitaxel-xrp-6258-in-previously-treated-advanced-non-small-cell-lung-cancer-nsclc-patients
#6
Ankit Madan, Benjamin S Jones, Rodolfo Bordoni, Mansoor N Saleh, Mary S Jerome, Deborah K Miley, Bradford E Jackson, Francisco Robert
PURPOSE: Given the success of cabazitaxel in patients with prostate cancer who progressed after receiving prior chemotherapy, its preclinical efficacy in various cell lines and possible ability to cross blood-brain barrier, cabazitaxel was hypothesized to increase objective response rate (ORR) in second-line setting in non-small cell lung cancer (NSCLC). METHODS: This was a phase II 2-stage trial in 28 patients using two different treatment schedules (A: 20 mg/m(2) every 3 weeks intravenously and B: 8...
September 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/26185001/androgen-deprivation-of-prostate-cancer-leading-to-a-therapeutic-dead-end
#7
REVIEW
Arndt Katzenwadel, Philipp Wolf
Androgen deprivation therapy (ADT) is considered as the standard therapy for men with de novo or recurrent metastatic prostate cancer. ADT commonly leads to initial biochemical and clinical responses. However, several months after the beginning of treatment, tumors become castration-resistant and virtually all patients show disease progression. At this stage, tumors are no longer curable and cancer treatment options are only palliative. In this review, we describe molecular alterations in tumor cells during ADT, which lead to deregulation of different signaling pathways and castration-resistance, and how they might interfere with the clinical outcome of different second-line therapeutics...
October 10, 2015: Cancer Letters
https://www.readbyqxmd.com/read/25374913/revisiting-nomenclature-for-the-description-of-prostate-cancer-androgen-responsiveness
#8
REVIEW
Hannelore V Heemers, James L Mohler
Ever since the Noble prize-winning findings of Huggins and Hodges, the androgen receptor (AR) has been the main target for treatment of advanced prostate cancer (CaP). Today, second- and even third-line androgen deprivation strategies, which have been designed rationally to interfere with the AR signaling that re-emerges under conditions of androgen deprivation and is at least in part responsible for disease recurrence, are effective in impeding progression of advanced CaP. The therapeutic success of these novel agents in CaP that has failed initial androgen deprivation therapy (ADT) and subsequent chemotherapy is prompting studies to explore their use earlier in the course of CaP progression...
2014: American Journal of Clinical and Experimental Urology
https://www.readbyqxmd.com/read/25344864/androgen-deprivation-therapy-sensitizes-prostate-cancer-cells-to-t-cell-killing-through-androgen-receptor-dependent-modulation-of-the-apoptotic-pathway
#9
Andressa Ardiani, Sofia R Gameiro, Anna R Kwilas, Renee N Donahue, James W Hodge
Despite recent advances in diagnosis and management, prostrate cancer remains the second most common cause of death from cancer in American men, after lung cancer. Failure of chemotherapies and hormone-deprivation therapies is the major cause of death in patients with castration-resistant prostate cancer (CRPC). Currently, the androgen inhibitors enzalutamide and abiraterone are approved for treatment of metastatic CRPC. Here we show for the first time that both enzalutamide and abiraterone render prostate tumor cells more sensitive to T cell-mediated lysis through immunogenic modulation, and that these immunomodulatory activities are androgen receptor (AR)-dependent...
October 15, 2014: Oncotarget
https://www.readbyqxmd.com/read/25099185/abiraterone-acetate-and-prednisolone-for-metastatic-castration-resistant-prostate-cancer-failing-androgen-deprivation-and-docetaxel-based-chemotherapy-a-phase-ii-bridging-study-in-korean-and-taiwanese-patients
#10
RANDOMIZED CONTROLLED TRIAL
Cheol Kwak, Tony Tong Lin Wu, Hyun Moo Lee, Hsi Chin Wu, Sung Joon Hong, Yen Chuan Ou, Seok Soo Byun, Hyou Young Rhim, Thian Kheoh, Ying Wan, Howard Yeh, Margaret K Yu, Choung Soo Kim
OBJECTIVES: To evaluate the safety and efficacy of abiraterone acetate and prednisolone in Korean and Taiwanese patients with metastatic castration-resistant prostate cancer not responding to docetaxel-based chemotherapy. METHODS: In this single-arm study, 82 metastatic castration-resistant prostate cancer patients who failed docetaxel-based chemotherapy were treated with abiraterone (1000 mg, once daily) and prednisolone (5 mg, twice daily). Patients achieving a prostate-specific antigen decline ≥ 50% were considered as responding...
December 2014: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/24971356/bioclinical-parameters-driving-decision-making-of-subsequent-lines-of-treatment-in-metastatic-castration-resistant-prostate-cancer
#11
REVIEW
A Irelli, G Bruera, K Cannita, E Palluzzi, G L Gravina, C Festuccia, C Ficorella, E Ricevuto
Different options are available as second-line treatment of metastatic castrate-resistant prostate cancer: cabazitaxel, abiraterone, and enzalutamide. Phase III studies evaluating cabazitaxel and the two hormonal agents have been shown to significantly prolong overall survival compared to mitoxantrone and placebo, respectively. Several studies have also demonstrated feasibility and activity of docetaxel rechallenge in case of a sufficient progression-free interval (3-6 months), good performance status, and previous acceptable safety profile, thus providing an additional treatment option in clinical practice...
2014: BioMed Research International
https://www.readbyqxmd.com/read/24870772/third-line-hormonal-therapy-to-treat-prostate-cancer-relapse-after-initial-and-second-line-hormonal-therapy-report-of-52-cases-and-literature-review
#12
REVIEW
Kazuhiro Matsumoto, Masayuki Hagiwara, Nozomi Hayakawa, Nobuyuki Tanaka, Yujiro Ito, Takahiro Maeda, Akiharu Ninomiya, Hirohiko Nagata, So Nakamura
The aim of this study was to evaluate the efficacy of third-line combined androgen blockade (CAB) therapy for castration-resistant prostate cancer that relapsed after primary and second-line CAB. We retrospectively reviewed the medical records of 52 patients who received first-, second-, and third-line CAB therapy (medical or surgical castration, plus steroidal antiandrogen of chlormadinone acetate, or nonsteroidal antiandrogen of flutamide or bicalutamide). For cumulative analysis, we searched the PubMed database and identified a total of 50 cases published in English...
2014: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/24516203/development-of-nomogram-to-non-steroidal-antiandrogen-sequential-alternation-in-prostate-cancer-for-predictive-model
#13
MULTICENTER STUDY
Naoto Kamiya, Hiroyoshi Suzuki, Kensaku Nishimura, Motohiro Fujii, Takatsugu Okegawa, Tadashi Matsuda, Tatsuo Morita, Yoshio Takihana, Seiichiro Ozono, Mikio Namiki, Akio Matsubara, Tomohiko Ichikawa, Tsuneharu Miki
OBJECTIVES: To clarify clinical predictors for a prostate-specific antigen decrease ≥50% in response to alternative non-steroidal antiandrogen therapy and to develop a nomogram to predict the prostate-specific antigen decrease ≥50% in response to alternative non-steroidal antiandrogen therapy in patients with advanced prostate cancer that relapsed after initial combined androgen blockade. We previously reported that combined androgen blockade with an alternative non-steroidal antiandrogen is effective for advanced prostate cancer that has relapsed after initial combined androgen blockade...
March 2014: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/24321502/eau-guidelines-on-prostate-cancer-part-ii-treatment-of-advanced-relapsing-and-castration-resistant-prostate-cancer
#14
REVIEW
Axel Heidenreich, Patrick J Bastian, Joaquim Bellmunt, Michel Bolla, Steven Joniau, Theodor van der Kwast, Malcolm Mason, Vsevolod Matveev, Thomas Wiegel, Filiberto Zattoni, Nicolas Mottet
OBJECTIVE: To present a summary of the 2013 version of the European Association of Urology (EAU) guidelines on the treatment of advanced, relapsing, and castration-resistant prostate cancer (CRPC). EVIDENCE ACQUISITION: The working panel performed a literature review of the new data (2011-2013). The guidelines were updated, and levels of evidence and/or grades of recommendation were added to the text based on a systematic review of the literature that included a search of online databases and bibliographic reviews...
February 2014: European Urology
https://www.readbyqxmd.com/read/24255983/enzalutamide-treatment-in-patients-with-metastatic-castration-resistant-prostate-cancer-progressing-after-chemotherapy-and-abiraterone-acetate
#15
Frederik Birkebaek Thomsen, Martin Andreas Røder, Per Rathenborg, Klaus Brasso, Michael Borre, Peter Iversen
OBJECTIVE: The aim of this study was to record prostate-specific antigen (PSA) response and overall survival (OS) for a group of metastatic castration-resistant prostate cancer (mCRPC) patients treated with enzalutamide following progression after abiraterone treatment in the post-chemotherapy setting. MATERIAL AND METHODS: Twenty-four mCRPC patients with progression after abiraterone treatment following primary docetaxel therapy received enzalutamide 160 mg/day...
June 2014: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/24136890/prognostic-model-predicting-metastatic-castration-resistant-prostate-cancer-survival-in-men-treated-with-second-line-chemotherapy
#16
RANDOMIZED CONTROLLED TRIAL
Susan Halabi, Chen-Yen Lin, Eric J Small, Andrew J Armstrong, Ellen B Kaplan, Daniel Petrylak, Cora N Sternberg, Liji Shen, Stephane Oudard, Johann de Bono, Oliver Sartor
BACKGROUND: Several prognostic models for overall survival (OS) have been developed and validated in men with metastatic castration-resistant prostate cancer (mCRPC) who receive first-line chemotherapy. We sought to develop and validate a prognostic model to predict OS in men who had progressed after first-line chemotherapy and were selected to receive second-line chemotherapy. METHODS: Data from a phase III trial in men with mCRPC who had developed progressive disease after first-line chemotherapy (TROPIC trial) were used...
November 20, 2013: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/24048789/ixabepilone-mitoxantrone-and-prednisone-for-metastatic-castration-resistant-prostate-cancer-after-docetaxel-based-therapy-a-phase-2-study-of-the-department-of-defense-prostate-cancer-clinical-trials-consortium
#17
MULTICENTER STUDY
Andrea L Harzstark, Jonathan E Rosenberg, Vivian K Weinberg, Jeremy Sharib, Charles J Ryan, David C Smith, Lance C Pagliaro, Tomasz M Beer, Glenn Liu, Eric J Small
BACKGROUND: Mitoxantrone plus prednisone and ixabepilone each have modest activity as monotherapy for second-line chemotherapy in patients with docetaxel-refractory castration-resistant prostate cancer. Clinical noncross- resistance was previously observed. Phase 1 testing determined the maximum tolerated dose and dose-limiting toxicities with the combination regimen; a phase 2 study was conducted to evaluate the activity of the combination. METHODS: Patients with metastatic progressive castration-resistant prostate cancer during or after 3 or more cycles of taxane-based chemotherapy enrolled in a phase 2 multicenter study of ixabepilone 35 mg/m(2) and mitoxantrone 12 mg/m(2) administered on Day 1 every 21 days with pegfilgrastim support, along with prednisone 5 mg twice daily...
June 1, 2011: Cancer
https://www.readbyqxmd.com/read/23979793/abiraterone-acetate-targeting-persistent-androgen-dependence-in-castration-resistant-prostate-cancer
#18
REVIEW
Lauren C Harshman, Mary-Ellen Taplin
Abiraterone acetate is the first second-line hormonal agent proven to improve survival in metastatic castration-resistant prostate cancer. It selectively inhibits cytochrome P450 17 (CYP17) α-hydroxylase and cytochrome17,20 (C17,20)-lyase, which are enzymes critical for androgen synthesis. Abiraterone acetate was initially approved in the United States in 2011 after demonstrating a 4-month survival benefit in docetaxel-refractory metastatic prostate cancer. The FDA recently expanded its indication for use in the pre-chemotherapy setting after it elicited significant delays in disease progression and a strong trend for increased overall survival in phase III studies...
August 2013: Advances in Therapy
https://www.readbyqxmd.com/read/23904851/pleuropulmonary-and-lymph-node-progression-after-docetaxel-benefits-from-treatment-with-cabazitaxel-in-metastatic-prostate-cancer
#19
Angel Segura Huerta, Encarnación Reche Santos, Gema Bruixola Campos, Carmen Salvador Coloma, Oscar Niño Gómez
INTRODUCTION: To date, there are no guidelines for a rational and more favourable sequence of treatment after docetaxel. Two drugs (cabazitaxel and abiraterone) have recently been approved as second-line treatment after docetaxel failure in metastatic castration-resistant prostate cancer (mCRPC), but there are no studies comparing abiraterone versus cabazitaxel. The most suitable drug is chosen based on the physician's opinion and the patient's characteristics. In patients with a good performance status who are able to receive either treatment, it would be convenient to begin with cabazitaxel and to reserve abiraterone in case there is a worsening of the general status, in consideration of abiraterone's more favourable toxicity profile...
May 2013: Case Reports in Oncology
https://www.readbyqxmd.com/read/23896627/are-post-docetaxel-treatments-effective-in-patients-with-castration-resistant-prostate-cancer-and-performance-of-2-a-meta-analysis-of-published-trials
#20
R Iacovelli, A Altavilla, G Procopio, S Bracarda, M Santoni, S Cascinu, E Cortesi
BACKGROUND: About 20% of patients with prostate cancer have an ECOG performance status (PS) 2 at diagnosis. We investigate if current treatment options for castration-resistant prostate cancer (CRPC) may decrease the risk of death even in patients with ECOG PS of 2. METHODS: PubMed was reviewed for phase III randomized trials in patients with CRPC progressed after docetaxel chemotherapy. Characteristics of each study and the relative hazard ratio (HR) for overall survival and 95% confidence interval (CI) were collected...
December 2013: Prostate Cancer and Prostatic Diseases
keyword
keyword
82408
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"